CRISPR News and Research

Latest CRISPR News and Research

Scientists map the genetic landscape of drug resistance in cancers

All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, helping to uncover targets for drug development and identify potential effective second-line therapies.

18 Oct 2024

Assessing and addressing IP staffing needs in a pediatric setting

A new paper published today in the American Journal of Infection Control (AJIC) describes efforts at a major children's hospital to assess and fulfill its staffing needs for infection prevention and control, highlighting the challenges of allocating sufficient resources to this important role.

17 Oct 2024

Adenine base editors show potential to correct X-CGD-causing mutations

A collaborative effort between investigators at the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder characterized by high susceptibility to infections.

16 Oct 2024

Bacteriophages unveil auxiliary genes critical for infection

Viruses that infect bacteria—known as bacteriophages - could be used in a targeted manner to combat bacterial diseases.

16 Oct 2024

Gene editing restores treatment sensitivity in melanoma

In a potential advance for melanoma patients, researchers at ChristianaCare’s Gene Editing Institute have used CRISPR gene editing tools to disable a gene mutation often seen in aggressive forms of this dangerous skin cancer that renders promising treatments ineffective.

16 Oct 2024

Harnessing the power of miRNA for cancer diagnosis and treatment

This study is led by Dr. Shiwei Duan (Department of Clinical Medicine, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China). His team analyzed literature on miRNA, summarizing the close relationship between these small molecules and cancer. miRNA is a type of non-coding RNA that does not encode proteins, but can target more than 60% of human protein-coding genes.

15 Oct 2024

Anne Bang joins research to understand the genetic underpinnings of psychiatric conditions

Scientists have linked neuropsychiatric disorders, such as schizophrenia and autism, to changes in many genes involved in early brain development.

12 Oct 2024

Grant supports gene-editing research for rare metabolic diseases

A $14M grant will fund research on gene-editing therapies for rare metabolic diseases at the Perelman School of Medicine at the University of Pennsylvania (Penn) and Children's Hospital of Philadelphia (CHOP).

10 Oct 2024

CRISPR-based rapid molecular diagnostic developed for two forms of leukemia

Researchers at Dana-Farber Cancer Institute have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions.

9 Oct 2024

Transposable elements found to be dysregulated in Alzheimer's brains, revealing potential targets for therapy

Study reveals widespread dysregulation of transposable elements (TEs) in aging human brains with Alzheimer's disease, using advanced techniques like CRISPR interference to identify TE-related risk genes.

9 Oct 2024

Overcoming CRISPR's side effects for therapeutic applications

CRISPR is a revolutionary tool that allows scientists to precisely modify the genome and gene expression of cells in any organism. It's a reagent - a substance that facilitates a reaction - that combines an enzyme with a programmable RNA capable of locating specific genetic sequences. Once guided to the correct spot, the enzyme acts like a pair of scissors, cutting, replacing, or deleting sequences of DNA.

7 Oct 2024

When CDK12/13 stalls, healthy prostate cells take a malignant turn

CDK12 is established as a tumor suppressor in prostate cancer, with its loss driving aggressive disease and creating vulnerabilities for targeted therapies.

7 Oct 2024

Novel lipid nanoparticles enhance tissue-specific drug delivery

Penn Engineers have discovered a novel means of directing lipid nanoparticles (LNPs), the revolutionary molecules that delivered the COVID-19 vaccines, to target specific tissues, presaging a new era in personalized medicine and gene therapy.

1 Oct 2024

ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement

Université de Montréal gains access to ERS Genomics' CRISPR/Cas9 patents, launching platforms for genome-wide screening and fostering research collaborations.

From ERS Genomics 1 Oct 2024

CRISPR-Cas13 emerges as a game changer in RNA-targeted therapies

In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the development of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) systems.

25 Sep 2024

Researchers gain new understanding of how immune cells respond to heat during fever

The study reveals that moderate fever enhances CD4 T cell activity while reducing regulatory T cell suppression, highlighting temperature's immune effects.

25 Sep 2024

New CRISPR model offers deeper insight into prostate cancer metastasis

A new preclinical model using CRISPR, an advanced technology that allows scientists to cut and edit genes, has given Weill Cornell Medicine researchers and their colleagues a deeper insight into how prostate cancer spreads or metastasizes.

23 Sep 2024

The role of CRISPR-Cas9 in combating mosquito-borne diseases

Announcing a new article publication for Zoonoses journal. As global warming increases, mosquito activity areas are expanding, alongside changes in the natural environment and the misuse of insecticides, thus further increasing mosquito resistance and exposing the world to an elevated risk of mosquito-borne diseases.

23 Sep 2024

Enhanced TnpB protein offers new possibilities for gene editing

CRISPR-Cas is used broadly in research and medicine to edit, insert, delete or regulate genes in organisms. TnpB is an ancestor of this well-known "gene scissor" but is much smaller and thus easier to transport into cells.

23 Sep 2024

MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, today announced they are entering into a strategic platform license (SPL) agreement.

From MaxCyte, Inc. 23 Sep 2024